MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease

    T. Willows, N. Dizdar, D. Nyholm, H. Widner, P. Grenholm, U. Schmiauke, A. Urbom, K. Groth, J. Larsson, J. Permert, S. Kjellander (Huddinge, Sweden)

    Objective: To demonstrate feasibility of TM for LCIG home titration, evaluate resource use, and assess patient, neurologist and nurse satisfaction. Background: LCIG, is used for…
  • 2016 International Congress

    Safety, pharmacokinetics, and efficacy of levodopa prodrug ONO-2160/CD: A study in patients with Parkinson’s disease

    M. Nomoto, M. Nagai, N. Nishikawa, Y. Kagamiishi, K. Yano, M. Akisada, S. Saito, M. Yuba, A. Takeda (Tohon Ehime, Japan)

    Objective: The objective of this study was to evaluate the safety, pharmacokinetic profile, and efficacy of ONO-2160/carbidopa (CD) and to compare them with an immediate-release…
  • 2016 International Congress

    Effects of levodopa on adaptation of reactive stepping in people with Parkinson’s disease

    F.B. Horak, B. Dijstra, J.G. Nutt, D.S. Paterson (Portland, OR, USA)

    Objective: Participants with PD were able to improve postural stepping responses with practice and this learning was improved by levodopa. Background: Protective steps in response…
  • 2016 International Congress

    A double blind investigation of efficacy and safety of incobotulinumtoxinA in Parkinson’s disease tremor- A customized injection approach

    S.O. Mittal, R. Rostami, D.G. Machado, D. Richardson, B. Jabbari (Cleveland, OH, USA)

    Objective: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection in the tremor of Parkinson's disease (PD). Background: Unlike other cardinal motor features of…
  • 2016 International Congress

    Adenosine A2A receptor antagonist istradefylline might have efficacy to fatigue and depression in some patients of Parkinson’s disease

    H. Ito, T. Kamei (Fujisawa, Japan)

    Objective: To evaluate the efficacy of istradefylline, a selective adenosine A2A receptor antagonist, for fatigue and depression in Parkinson's disease (PD) patients. Background: Istradefylline is…
  • 2016 International Congress

    Voice harmonic amplitude differences before and after LSVT LOUDTM in Parkinson’s disease

    M.P. Cannito, L.O. Ramig, A.E. Halpern, J.L. Spielman (Lafayette, LA, USA)

    Objective: To evaluate voice harmonic amplitudes from acoustic spectra of speech produced by subjects with Parkinson's disease (PD) before and after voice treatment, in order…
  • 2016 International Congress

    Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

    M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

    Objective: We analyzed diurnal variation of levodopa plasma concentration in large number of patients with Parkinson's disease (PD) to clarify the pattern of diurnal variation.…
  • 2016 International Congress

    Pharmacokinetic profile of ONO-2160/CD (levodopa prodrug/carbidopa) in animal and human

    M. Nomoto, M. Nagai, N. Nishikawa, K. Yano, Y. Kagamiishi, M. Akisada, S. Saito, M. Yuba, T. Koyanagi, A. Takeda (Tohon Ehime, Japan)

    Objective: The objective of this study was to characterize pharmacokinetic profile of levodopa prodrug ONO-2160 in animal and human. Background: Motor complications of Parkinson's disease…
  • 2016 International Congress

    Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents

    M.J. Matos, D. Viña, F. Rodríguez-Enríquez, S. Vilar, L. Santana, E. Uriarte (Santiago de Compostela, Spain)

    Objective: Taking into account the background of our research group and the knowledge that MAO and ChE activity generates ROS that cause neuronal cell death,…
  • 2016 International Congress

    Pisa syndrome in Parkinson’s disease: A mobile orfixed deformity?

    E.I. Giyazitdinova, B.T. Muinjonov, G.S. Rakhimbaeva, Y.A. Musaeva, F.K. Shermukhamedova (Taskent, Uzbekistan)

    Objective: To study of Pisa syndrome in Parkinson's disease. Background: Although Pisa syndrome and scoliosis are sometimes used interchangeably to describe a laterally flexed postural…
  • « Previous Page
  • 1
  • …
  • 1530
  • 1531
  • 1532
  • 1533
  • 1534
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley